Presentation will demonstrate safety and immunogenicity, provide an update on NIH-funded bird flu trial, and highlight the technology’s potential in pandemic preparedness.
News
- H5 Influenza (Pandemic Flu) Clinical Trial Successful, Peer-Reivewed and Accepted for Publication
- BlueWillow Biologics to Present Significant Progress on Its Novel Intranasal Vaccine Technology at World Vaccine Congress Europe
- Dr. Shabaana Khader, University of Chicago, highlights promise of intranasal mucosal vaccine strategy for tuberculosis.
Contact
BlueWillow Biologics, Inc.
2311 Green Rd. Suite A
Ann Arbor, MI 48105
734-302-4000
734-302-9150 fax
